突发发作的严重血小板缺血 继发于trimethoprim-Sulfamethoxazole
Jonathan Spadafora1, Philip Spadafora1, James Spadafora1
1College of Osteopathic Medicine, New York Institute of Technology, Old Westbury, USA.
Cureus
|September 10, 2025
概括
三甲-硫甲醇 (TMP-SMX) 可以引起药物诱导的免疫血小板缺血 (DITP),血小板的危险下降. 早期识别和停止药物治疗对于患者的康复和预防严重出血至关重要.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 药物诱导的免疫血小板缺血 (DITP) 是一种罕见的,严重的疾病.
- 它涉及药物依赖的抗体攻击血小板.
- 三甲-硫甲醇 (TMP-SMX) 是一个潜在的原因.
研究的目的:
- 报告一个DITP病例.
- 强调早期诊断和戒药的重要性.
- 强调临床诊断,而不是延迟抗体检测.
主要方法:
- 一个57岁的男性患者的病例报告.
- 临床表现为严重的血小板缺血和出血.
- 实验室检测包括血小板计数和不成熟血小板分数 (IPF).
主要成果:
- 患者在TMP-SMX后出现严重的血小板缩 (1 × 103/μL) 和出血.
- 感染和自身免疫性工作是负的.
- 在停止TMP-SMX和支持性护理后,血小板数恢复.
结论:
- TMP-SMX可以触发DITP.
- 迅速识别和撤销致病原体至关重要.
- 临床诊断通常是DITP管理的最实用的方法.
相关概念视频
Combined Effects of Drugs: Synergism
6.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
6.8K
Venous Thrombosis III: Interprofessional Care
280
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
280
Disorders of Hemostasis
2.0K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.0K
Pulmonary Tuberculosis I
846
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
846
Therapeutic Drug Monitoring: Affecting Factors
202
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
202
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K


